Retrospective studies on using proton therapy and carbon ion therapy for sinonasal carcinoma including a patient with SMARCB1-deficient sinonasal carcinoma could achieve a local and regional control rate of about 85%, with very limited grade 3 or 4 toxicities [62,63,64,65,66,67]. The gene discussed is SMARCB1; the disease is nasal cavity and paranasal sinus carcinoma.